Archives
-
Aging, Mitochondrial ROS, and Macrophage Phagocytosis
2026-09-16
The reference study identifies a mechanistic chain linking aging-related mitochondrial reactive oxygen species to excess collagen production, impaired F-actin turnover, and defective macrophage phagocytosis. Its combination of human and mouse models, RNA-seq, molecular perturbation, and in vivo validation provides a framework for studying immune aging beyond inflammatory cytokine measurements.
-
Cisapride in iPSC-CM Cardiotoxicity Screens
2026-09-15
Cisapride, also known as R 51619, can serve as a mechanistically informative challenge compound in iPSC-derived cardiomyocyte assays. This article explains how to combine its 5-HT4 activity and hERG channel inhibition with deep-learning phenotyping for more defensible cardiac safety decisions.
-
Mecamylamine Hydrochloride in Gut-Brain Assays
2026-09-15
Mecamylamine hydrochloride provides a brain-penetrant, non-competitive nAChR challenge for separating cholinergic receptor effects from microbiota-driven signaling. This workflow connects receptor pharmacology with vagal, seizure, and neuropsychiatric disorder research while emphasizing vehicle control, concentration-response design, and pathway-level validation.
-
In Vitro Embryonic Dormancy Through mTOR Inhibition
2026-09-14
The Nature Protocols paper establishes a noninvasive, scalable framework for placing mouse blastocysts, human blastoids, and pluripotent stem cells into a reversible diapause-like state through pharmacological mTOR inhibition. Its main practical contribution is a unified workflow for inducing, maintaining, and reversing dormancy while distinguishing genuine developmental quiescence from nonspecific loss of viability.
-
PBS Liposomes: Controls for Causal Inference
2026-09-14
PBS Liposomes provide a biologically restrained comparator for macrophage depletion experiments. This article connects their use as a clodronate control with structure-guided pharmacology, showing how matched controls improve causal interpretation without conflating distinct biological systems.
-
Calpain Inhibitor I, ALLN: Practical Lab Guide
2026-09-13
Calpain Inhibitor I, ALLN (SKU A2602) provides a DMSO-compatible way to investigate calpain- and cathepsin-linked proteolysis in apoptosis, inflammation, and ischemia-reperfusion workflows. It should not be treated as a calpain-only probe, used in water-based formulations, or applied for diagnostic or medical purposes.
-
Neuromedin S (rat): Practical GPCR Protocol
2026-09-12
Neuromedin S (rat), SKU B5466, provides a defined rat peptide ligand for controlled neuromedin U receptor signaling and GPCR/G protein assay development. This guide covers preparation, handling, controls, and QC; it does not assign potency or support diagnostic, therapeutic, or unvalidated in vivo use.
-
A Proximity MAP of RAB GTPases: Methods and Findings
2026-09-11
The preprint A Proximity MAP of RAB GTPases applies APEX2 proximity labeling to 23 human RAB proteins, generating a comparative resource of their neighboring proteomes. Its validation of RAB25–DENND6A and RAB14-associated trafficking relationships shows how proximity maps can reveal transient regulatory connections that conventional interaction assays may miss.
-
CCK-8, Electroacupuncture Analgesia, and Tolerance
2026-09-11
The reference study identified central cholecystokinin octapeptide as an anti-opioid modulator that suppresses electroacupuncture analgesia and contributes to electroacupuncture tolerance in rats. Its combination of exogenous peptide administration and CCK-8 antiserum provided mechanistic evidence that endogenous CCK-8 may counteract opioid signaling without changing baseline nociception.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-09-10
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a more discriminating framework for interpreting proliferation arrest, cell killing, response timing, and assay design in vitro.
-
Isoprenaline Hydrochloride: Research Guide
2026-09-10
Isoprenaline Hydrochloride, also called isoproterenol, is a non-selective β-adrenoceptor agonist for controlled β1- and β2-receptor stimulation. Its documented uses include cardiac arrhythmia research, endothelial angiogenesis assays, bronchospasm research, and mouse heart–brain studies, but preclinical findings do not establish clinical efficacy.
-
U-73122: From PLC Inhibition to Invasion Assays
2026-09-09
U-73122 is a phospholipase C inhibitor for connecting calcium signaling with cell migration and breast cancer invasion. This guide translates mechanistic evidence into better assay design, controls, and interpretation beyond a conventional product overview.
-
Cy3-UTP for Fluorescent RNA Labeling
2026-09-09
Cy3-UTP is a Cy3-modified uridine triphosphate for producing fluorescent RNA during in vitro transcription. Its water solubility, reported 95% purity, and light-protected storage requirement support controlled RNA imaging, RNA-protein interaction studies, and RNA detection assays.
-
Cy3-dCTP: From Labeling to Assay Design
2026-09-08
Cy3-dCTP enables covalent fluorescent labeling of DNA and cDNA while preserving a broad polymerase workflow. This guide connects Cyanine 3-deoxycytidine triphosphate selection with enzyme accessibility, probe architecture, and practical assay optimization.
-
D-Luciferin Workflows for Tumor BLI
2026-09-08
D-Luciferin supports sensitive firefly luciferase readouts for intracellular ATP quantification, promoter-driven reporter monitoring, and longitudinal tumor burden assessment. This practical guide connects assay setup and troubleshooting with a tumor-targeted immunotherapy framework while clearly separating established evidence from proposed imaging extensions.